Protein kinase A

Protein kinase A
Name	Protein kinase A

Protein kinase A is a ubiquitously expressed serine/threonine kinase that transduces cyclic adenosine monophosphate signals into phosphorylation events coordinating metabolism, transcription, and cell growth. First characterized in classical biochemical studies, it occupies a central node connecting receptors such as β-adrenergic receptor, glucagon receptor, and dopamine receptor D1 to intracellular effectors including CREB, Glycogen synthase kinase 3, and components of the mTOR signaling pathway. Its discovery and biochemical dissection informed research in laboratories associated with institutions like Cold Spring Harbor Laboratory, Max Planck Society, and Massachusetts Institute of Technology.

Structure and Isoforms

The holoenzyme is a tetrameric complex composed of two catalytic (C) subunits and a regulatory (R) subunit dimer; crystallographic work from groups at European Molecular Biology Laboratory and Stanford University revealed conserved bilobed kinase cores and regulatory docking interfaces. Mammalian genomes encode multiple C isoforms such as Cα, Cβ, and Cγ identified in studies at National Institutes of Health and Salk Institute, and R isoforms (RIα, RIβ, RIIα, RIIβ) discovered in genetic screens at University of California, San Francisco and Harvard Medical School. Alternative splicing and promoter usage produce tissue-specific variants; clinical genetics literature from Johns Hopkins University and University of Cambridge links RIα mutations to endocrine disorders mapped in population cohorts by researchers at Wellcome Trust and Broad Institute. Structural motifs include the activation loop, ATP-binding pocket, glycine-rich loop, and the pseudosubstrate docking site characterized by electron microscopy groups at Max Planck Institute for Biophysical Chemistry.

Activation and Regulation

Activation is controlled by cyclic AMP produced by adenylate cyclases downstream of G protein–coupled receptors such as β-adrenergic receptor and MC4R; regulatory inputs from G proteins were mapped in classic studies at Rockefeller University. cAMP binds to cyclic nucleotide binding domains on R subunits, provoking release of active C subunits; modulation by phosphodiesterases including PDE4 and PDE3, characterized at University of Oxford and Imperial College London, shapes temporal dynamics. A-kinase anchoring proteins (AKAPs) such as AKAP79/150 scaffold PKA near substrates and phosphatases; AKAP biology has been advanced by investigators at Duke University and Yale University. Post-translational regulation involves myristoylation of certain C isoforms reported by researchers at University of Toronto, proteasomal turnover studied at European Molecular Biology Laboratory, and feedback inhibition via protein phosphatases like PP1 and PP2A analyzed at University of California, Berkeley.

Catalytic Mechanism and Substrate Specificity

The catalytic cycle uses ATP as phosphoryl donor with coordination by conserved residues in the hinge and catalytic loop; mechanistic enzymology was elucidated by laboratories at Max Planck Institute for Molecular Physiology and University of Cambridge. Substrate recognition favors the Arg-Arg-X-Ser/Thr consensus motif, a specificity motif first described by studies at University of Chicago and refined in phosphoproteomics consortia at EMBL-EBI. Kinetic parameters (kcat, Km) vary among isoforms and are modulated by cofactors and inhibitor proteins characterized at University of Pennsylvania and Massachusetts General Hospital. Structural comparisons link PKA’s active site geometry to other kinases including Cyclin-dependent kinase 2 and Protein kinase C determined by collaborative projects at European Synchrotron Radiation Facility.

Cellular Functions and Signaling Pathways

PKA phosphorylates transcription factors such as CREB and regulators of metabolism including Hormone-sensitive lipase and Glycogen phosphorylase, integrating hormonal cues studied in teams at University of Michigan and University of Texas Southwestern Medical Center. It cross-talks with pathways governed by MAPK/ERK pathway, Wnt signaling pathway, and PI3K/AKT pathway in contexts ranging from neuronal plasticity investigated at Columbia University to immune modulation reported by groups at National Institute of Allergy and Infectious Diseases. In cardiac myocytes, PKA phosphorylates ion channels like L-type calcium channels and troponin I; cardiology research from Cleveland Clinic and Mayo Clinic linked these events to contractility and arrhythmogenesis. In neurons, PKA regulates synaptic transmission and long-term potentiation described in studies at University College London and California Institute of Technology.

Role in Physiology and Disease

Genetic and clinical studies implicate PKA pathway alterations in disorders including Carney complex linked to PRKAR1A mutations reported by clinicians at Mayo Clinic and NIH Clinical Center, endocrine tumors studied at Memorial Sloan Kettering Cancer Center, and metabolic diseases elucidated at Harvard Medical School. Aberrant PKA signaling appears in psychiatric conditions linked to dopaminergic circuits investigated by teams at Yale School of Medicine and King's College London. Cardiac hypertrophy and heart failure involve dysregulated PKA activities identified in cohorts at Johns Hopkins Hospital and Mount Sinai Hospital. PKA’s role in cancer biology intersects with oncogenes such as RAS and tumor suppressors like p53; translational work at Dana-Farber Cancer Institute and Fred Hutchinson Cancer Center explores targeting PKA-related nodes.

Experimental Methods and Inhibitors

Biochemical assays include radioactive phosphorylation, kinase activity assays standardized in facilities at European Bioinformatics Institute and mass spectrometry–based phosphoproteomics performed by cores at Wellcome Sanger Institute and ProteomeXchange partners. Structural studies employ X-ray crystallography and cryo-EM at Diamond Light Source and National Center for Electron Microscopy. Genetic manipulation uses CRISPR approaches developed at Broad Institute and conditional mouse models from consortia at Jackson Laboratory. Pharmacological inhibitors include H-89 and KT5720 characterized in pharmacology labs at University of Freiburg and isoform-selective peptides developed by groups at University of California, San Diego; small-molecule modulators and chemical genetics screens are pursued at GlaxoSmithKline and Novartis for therapeutic exploration. Imaging of PKA activity employs FRET-based biosensors created by researchers at Stanford University and applied in live-cell studies at Max Delbrück Center for Molecular Medicine.

Category:Protein kinases